​

Innate Pharma (IPHA) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

IPHA Stock Rating

Innate Pharma stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

IPHA Price Target Upside V Benchmarks

TypeNameUpside
StockInnate Pharma-
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.98$1.98$1.98
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25111--3
May, 25111--3
Apr, 25111--3
Mar, 25121--4
Feb, 25121--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 13, 2024H.C. WainwrightBuyBuyhold
Nov 15, 2022SVB LeerinkOutperformOutperformhold
Sep 16, 2022CitigroupBuyBuyhold
Aug 02, 2022SVB LeerinkOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.90$-0.74$-1.24$-0.09-----
Avg Forecast$-0.42$-0.53$-0.30$-0.56$-0.30$0.17$0.78$-0.35$0.30
High Forecast$-0.42$-0.53$-0.07$-0.16$-0.09$0.32$1.42$-0.10$0.55
Low Forecast$-0.42$-0.53$-0.66$-1.02$-0.55$0.05$0.23$-0.65$0.09
Surprise %114.29%39.62%313.33%-83.93%-----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$56.83M$12.11M$49.64M$51.90M-----
Avg Forecast$76.14M$45.64M$67.65M$54.31M$45.59M$95.69M$181.79M$72.06M$148.00M
High Forecast$129.30M$45.64M$129.67M$60.08M$74.89M$157.18M$298.62M$118.37M$243.11M
Low Forecast$67.66M$45.64M$27.02M$48.55M$20.90M$43.87M$83.34M$33.03M$67.84M
Surprise %-25.36%-73.46%-26.62%-4.44%-----

Net Income Forecast

$-100M $-50M $0 $50M $100M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-70.75M$-59.14M$-99.10M$-7.57M-----
Avg Forecast$-34.10M$-42.59M$-24.06M$-44.65M$-24.17M$14.03M$62.42M$-28.44M$24.13M
High Forecast$-34.10M$-42.59M$-5.27M$-13.21M$-7.15M$25.75M$114.58M$-8.42M$44.29M
Low Forecast$-34.10M$-42.59M$-52.73M$-81.96M$-44.36M$4.15M$18.47M$-52.20M$7.14M
Surprise %107.44%38.86%311.98%-83.05%-----

IPHA Forecast FAQ

Is Innate Pharma stock a buy?

Innate Pharma stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Innate Pharma is a favorable investment for most analysts.

What is Innate Pharma's price target?

Innate Pharma's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.98.

How does Innate Pharma stock forecast compare to its benchmarks?

Innate Pharma's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (23.68%) and underperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Innate Pharma over the past three months?

  • June 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Innate Pharma’s EPS forecast?

Innate Pharma's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.3, marking a 233.33% increase from the reported $-0.09 in 2023. Estimates for the following years are $0.17 in 2025, $0.78 in 2026, $-0.35 in 2027, and $0.3 in 2028.

What is Innate Pharma’s revenue forecast?

Innate Pharma's average annual revenue forecast for its fiscal year ending in December 2024 is $45.59M, reflecting a -12.16% decrease from the reported $51.9M in 2023. The forecast for 2025 is $95.69M, followed by $181.79M for 2026, $72.06M for 2027, and $148M for 2028.

What is Innate Pharma’s net income forecast?

Innate Pharma's net income forecast for the fiscal year ending in December 2024 stands at $-24.171M, representing an 219.29% increase from the reported $-7.57M in 2023. Projections indicate $14.03M in 2025, $62.42M in 2026, $-28.437M in 2027, and $24.13M in 2028.